t705

Favipiravir is a potent and selective RNA-dependent RNA polymerase inhibitor for the treatment of influenza virus infections.

Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.

T-705RTP is a selective and GTP-competitive of influenza virus RNA polymerase(IC50 of 0.14 μM and a Ki of 1.52 μM), has potent anti-influenza virus activity.

T-705RTP sodium is a selective and GTP-competitive of influenza virus RNA polymerase(IC50 of 0.14 μM and a Ki of 1.52 μM), has potent anti-influenza virus activity.

T-705RMP, the phosphorylated metabolite derived from T-705, demonstrates a limited inhibitory impact on the host cells' IMP dehydrogenase (IMPDH) activities, with an IC 50 value of 601 μM.

Dalcetrapib (RO4607381), a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.

T-705RMP (ammonium), the ammonium form of T-705RMP, exhibits weak inhibition of IMP dehydrogenase (IMPDH) activity [1].

2'-Deoxy-2'-fluorocytidine, a nucleoside analog, is a potent inhibitor of Crimean-Congo hemorrhagic fever virus (CCHFV) replication and can act synergistically with T705 to enhance the antiviral effects on CCHFV replication[1]. It exhibits antiviral activity with EC50 values of 61 nM and 31 nM against CCHFV and CCHFV/ZsG in Huh7 cells, respectively, and has a CC50 of >50.0 μM in Huh7 cells[1]. [1]. Stephen R Welch, et al. Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antiviral Res. 2017 Nov;147:91-99.